Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

U Jäger, W Barcellini, CM Broome, MA Gertz, A Hill… - Blood reviews, 2020 - Elsevier
Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …

Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the writing committee of the American society for apheresis: the …

J Schwartz, A Padmanabhan, N Aqui… - Journal of clinical …, 2016 - Wiley Online Library
The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …

[HTML][HTML] Sutimlimab in cold agglutinin disease

A Röth, W Barcellini, S D'Sa, Y Miyakawa… - … England Journal of …, 2021 - Mass Medical Soc
Background Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized
by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a …

Guidelines on the use of therapeutic apheresis in clinical practice—evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …

J Schwartz, JL Winters, A Padmanabhan… - Journal of clinical …, 2013 - Wiley Online Library
The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is
charged with reviewing, updating and categorizating indications for therapeutic apheresis …

Cold agglutinin disease revisited: a multinational, observational study of 232 patients

S Berentsen, W Barcellini, S D'Sa… - Blood, The Journal …, 2020 - ashpublications.org
We retrospectively studied 232 patients with cold agglutinin disease (CAD) at 24 centers in 5
countries. In Norway and a northern region of Italy, the study was close to being population …

[HTML][HTML] New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia

S Berentsen - Frontiers in immunology, 2020 - frontiersin.org
Autoimmune hemolytic anemias mediated by cold agglutinins can be divided into cold
agglutinin disease (CAD), which is a well-defined clinicopathologic entity and a clonal …

The diagnosis and management of primary autoimmune haemolytic anaemia.

QA Hill, R Stamps, E Massey… - British journal of …, 2017 - search.ebscohost.com
The article presents guidelines for the diagnosis and management of patients with primary
autoimmune haemolytic anaemia (AIHA). Topics discussed include diagnostic approach to …

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients

W Barcellini, B Fattizzo, A Zaninoni… - Blood, The Journal …, 2014 - ashpublications.org
The clinical outcome, response to treatment, and occurrence of acute complications were
retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and …

[HTML][HTML] New insights in autoimmune hemolytic anemia: from pathogenesis to therapy

W Barcellini, A Zaninoni, JA Giannotta… - Journal of clinical …, 2020 - mdpi.com
Autoimmune hemolytic anemia (AIHA) is a highly heterogeneous disease due to increased
destruction of autologous erythrocytes by autoantibodies with or without complement …

[HTML][HTML] Treatment of autoimmune hemolytic anemias

A Zanella, W Barcellini - Haematologica, 2014 - ncbi.nlm.nih.gov
Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder caused by
autoantibodies directed against self red blood cells. It can be idiopathic or secondary, and …